Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Net Income (2017 - 2025)

Historic Net Income for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to -$79.1 million.

  • Autolus Therapeutics' Net Income rose 362.51% to -$79.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$224.8 million, marking a year-over-year increase of 1680.99%. This contributed to the annual value of -$220.7 million for FY2024, which is 589.25% down from last year.
  • As of Q3 2025, Autolus Therapeutics' Net Income stood at -$79.1 million, which was up 362.51% from -$47.9 million recorded in Q2 2025.
  • In the past 5 years, Autolus Therapeutics' Net Income ranged from a high of -$6.8 million in Q4 2021 and a low of -$44.8 billion during Q3 2021
  • Over the past 5 years, Autolus Therapeutics' median Net Income value was -$45.8 million (recorded in 2023), while the average stood at -$2.4 billion.
  • As far as peak fluctuations go, Autolus Therapeutics' Net Income crashed by 8428307.1% in 2021, and later skyrocketed by 9990.45% in 2022.
  • Quarter analysis of 5 years shows Autolus Therapeutics' Net Income stood at -$6.8 million in 2021, then crashed by 298.16% to -$27.0 million in 2022, then plummeted by 186.04% to -$77.2 million in 2023, then skyrocketed by 64.23% to -$27.6 million in 2024, then plummeted by 186.6% to -$79.1 million in 2025.
  • Its Net Income stands at -$79.1 million for Q3 2025, versus -$47.9 million for Q2 2025 and -$70.2 million for Q1 2025.